Analyzing Genocea Biosciences Inc. (GNCA) By Technical Indicators

As of Friday close, Genocea Biosciences Inc.’s (NASDAQ:GNCA) stock was up $0.05, moving up 33.85 percent to $0.22. The average number of shares traded per day over the past five days has been 4,934,420 shares. 3 times new highs have been achieved over the past 5 days, with a $0.0006 gain in that time frame. In the last twenty days, the average volume was 2,232,620, while in the previous 50 days, it was 2,690,976.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


Since last month, GNCA stock retreated -53.75%. Shares of the company fell to $0.1601 on 05/12/22, the lowest level in the past month. A 52-week high of $2.68 was reached on 04/04/22 after having rallying from a 52-week low of $0.16. Since the beginning of this year, GNCA’s stock price has dropped by -80.60% or -$0.9350, and marked a new high 5 times. However, the stock has declined by -91.60% since its 52-week high.

Genocea Biosciences Inc. (GNCA) last reported insider trading activity 40 days ago on Apr 04. Flechtner Jessica Baker, the Chief Scientific Officer of the company, disposed of 1,212 shares for $1.25 on Apr 04. It resulted in a $1,515 divestment by the insider. Duvall Diantha sold 963 shares at an average price of $1.25 on Apr 04. The insider now owns 91,775 shares following the transaction. On Apr 04, CHIEF MEDICAL OFFICER Davis Thomas Andrew sold 1,091 shares at $1.25 apiece. The transaction was valued at $1,364.

Valuation Metrics

The stock’s beta is 1.90. Besides these, the trailing price-to-sales (P/S) ratio of 9.04, the price-to-book (PB) ratio of 0.34.

Financial Health

In the three months ended September 29, Genocea Biosciences Inc.’s quick ratio stood at 1.40, while its current ratio was 1.40, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 0.23, and the total debt-to-equity ratio was 0.61. Based on annual data, GNCA earned $53.73 million in gross profit and brought in $1.64 million in revenue.

In Genocea Biosciences Inc.’s quarter-end financial report for September 29, it reported total debt of $2.95 million. GNCA’s revenue fell -214.81% to $0.39 million during the quarter, while net income inched up to $0.27 million. While analysts expected Genocea Biosciences Inc. to report -$0.2 quarterly earnings, the actual figure was -$0.05 per share, beating the consensus estimate by 75.00%. During the quarter, the company generated -$13.0 million in EBITDA. The liabilities of Genocea Biosciences Inc. were 28.89 million at the end of its most recent quarter ended September 29, and its total debt was $18.85 million. The value of shareholders’ equity is $58.73 million.

Technical Picture

This quick technical analysis looks at Genocea Biosciences Inc.’s (GNCA) price momentum. With a historical volatility rate of 182.62%, the RSI 9-day stood at 31.87% on 13 May.

With respect to its five-day moving average, the current Genocea Biosciences Inc. price is up by +0.27% percent or $0.0006. At present, GNCA shares trade -51.09% below its 20-day simple moving average and -76.46% percent below its 100-day simple moving average. However, the stock is currently trading approximately -78.77% below its SMA50 and -88.97% below its SMA200.

Stochastic coefficient K was 10.32% and Stochastic coefficient D was 4.83%, while ATR was 0.0679. Given the Stochastic reading of 24.97% for the 14-day period, the RSI (14) reading has been calculated as 29.20%. As of today, the MACD Oscillator reading stands at -0.0277, while the 14-day reading stands at -0.0764.

Analyst Ratings

SVB Leerink launched its rating on Genocea Biosciences Inc. (NASDAQ: GNCA) to an Outperform in a note to investors on November 15, 2019. Genocea Biosciences Inc. (GNCA) has been rated Overweight by analysts. According to 0 brokerage firms, GNCA is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Genocea Biosciences Inc. stock as buy, with 2 recommending it as overweight.

With a median target price of $5.50, the current consensus forecast for the stock is $0.16 – $9.00. Based on these forecasts, analysts predict Genocea Biosciences Inc. (GNCA) will achieve an average price target of $5.04.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles